TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11099374

Group type: EXPERIMENTAL
Intervention: CHO (6% carbohydrate‐electrolyte)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CHO + Cr+3 (CHO plus chromium picolinate 400 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: P (placebo)
Number of subjects: 8
Study: 9278198

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg(‐1)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (healthy patients)
Number of subjects: 38
Study: 8297447

Group type: EXPERIMENTAL
Intervention: naloxone (2 x 0.1 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no naloxone)
Number of subjects: 22
Study: 3026690

Group type: EXPERIMENTAL
Intervention: Prazosin premedication
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no prazosin)
Number of subjects: 8
Study: 30501612

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 26874885

Group type: EXPERIMENTAL
Intervention: Eribulin (1·4 mg/m² intravenously on days 1 and 8)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Dacarbazine (850 mg/m², 1000 mg/m², or 1200 mg/m² intravenously on day 1)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 452

Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 452
Study: 24303930

Group type: EXPERIMENTAL
Intervention: Pharmacist-administered, tailored, 1-year telephone-based intervention
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500
Study: 22828595

Group type: EXPERIMENTAL
Intervention: Zoster vaccine
Number of subjects: 7320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7320
Study: 20653723

Group type: EXPERIMENTAL
Intervention: Reflectance confocal microscopy (RCM)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: RCM
Number of subjects: 7
Study: 18306248

Group type: EXPERIMENTAL
Intervention: Nurse management
Number of subjects: 406

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 406
Study: 16401239

Group type: EXPERIMENTAL
Intervention: Olanzapine plus EGb (n=15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Olanzapine alone (n=14)
Number of subjects: 29
Study: 12795749

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg b.i.d, Clarithromycin 500 mg b.i.d, Tinidazole 500 mg b.i.d
Number of subjects: 94

Group type: COMPARATOR
Intervention: Rabeprazole 10 mg b.i.d, Clarithromycin 500 mg b.i.d, Tinidazole 500 mg b.i.d
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg b.i.d
Number of subjects: 94

Group type: COMPARATOR
Intervention: Rabeprazole 10 mg b.i.d
Number of subjects: 94
Study: 10386189

Group type: EXPERIMENTAL
Intervention: TRH stimulation test
Number of subjects: 15
Study: 8712425

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) bolus injection of meperidine 0.6 mg/kg and ketorolac 0.5 mg/kg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 49
Study: 1650106

Group type: EXPERIMENTAL
Intervention: Antidepressants (desipramine/petytyl) and incazane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bemityl (actoprotector)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sydnocarb (psychostimulant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pimozide (neuroleptic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combinations of sydnocarb and incazane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combinations of pimozide and incazane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone test, response to psychostimulants, and diazepam test
Number of subjects: 0
Study: 31738070

Group type: EXPERIMENTAL
Intervention: Multidimensional Forced-Choice (MFC) format
Number of subjects: 593

Group type: COMPARATOR
Intervention: Rating Scale (RS) format
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Both MFC and RS formats
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: MFC format
Number of subjects: 593

Group type: COMPARATOR
Intervention: RS format
Number of subjects: 593
Study: 30782097

Group type: EXPERIMENTAL
Intervention: Adzuki bean extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27578271

Group type: EXPERIMENTAL
Intervention: SEE IT training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Consensus coder ratings
Number of subjects: 50

Group type: COMPARATOR
Intervention: SP ratings
Number of subjects: 50
Study: 26505801

Group type: EXPERIMENTAL
Intervention: Relapse group (n=11)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Relapse-free group (n=13)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (n=24)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Relapse-risk assessment model
Number of subjects: 24
Study: 23374372

Group type: EXPERIMENTAL
Intervention: Exercise therapy in addition to diet therapy (n = 26)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: High-frequency exercise subgroup
Number of subjects: 51

Group type: COMPARATOR
Intervention: Diet therapy alone (n = 25)
Number of subjects: 51
Study: 21225293

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg rocuronium
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg rocuronium
Number of subjects: 24

Group type: COMPARATOR
Intervention: suxamethonium 1.5 mg/kg
Number of subjects: 24
Study: 19709328

Group type: EXPERIMENTAL
Intervention: Gentamicin (GM)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Amikacin (AK)
Number of subjects: 94
Study: 17228345

Group type: EXPERIMENTAL
Intervention: Milk (1.5 l/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Meat (250 g/day)
Number of subjects: 28
Study: 14732826

Group type: EXPERIMENTAL
Intervention: Adherence to hemodialysis guidelines and modifiable practices (dialysis dose, phosphate control, improved anemia, partial correction of serum albumin, reduced interdialytic weight gain, less use of catheters for vascular access)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Having albumin <3.5 g/dl
Number of subjects: 0
Study: 11601598

Group type: EXPERIMENTAL
Intervention: Childhood victimization (abuse and neglect)
Number of subjects: 582
Study: 9842820

Group type: EXPERIMENTAL
Intervention: Prophylactic metoprolol (maximal dose of 10 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Prophylactic glycopyrrolate (maximal dose of 6 microg/kg)
Number of subjects: 150
Study: 8128188

Group type: EXPERIMENTAL
Intervention: 10 mg cM-T412
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 50 mg cM-T412
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 100 mg cM-T412
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 29
Study: 2569998

Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine three times daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4 mg chlorpheniramine three times daily
Number of subjects: 20
Study: 406623

Group type: EXPERIMENTAL
Intervention: Smoking one cigarette
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no smoking)
Number of subjects: 25
Study: 31292172

Group type: EXPERIMENTAL
Intervention: Paravertebral blockade (PVB)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Thoracic epidural blockade (TEB)
Number of subjects: 69
Study: 29188883

Group type: EXPERIMENTAL
Intervention: DASHNa-CC intervention (usual care plus dietary intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 25985245

Group type: EXPERIMENTAL
Intervention: EUS-guided therapy with adalimumab (ADA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 20
Study: 24034093

Group type: EXPERIMENTAL
Intervention: Alprostadil plus statins
Number of subjects: 156

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 156
Study: 21214940

Group type: EXPERIMENTAL
Intervention: IPTc (monthly IPTc with a single dose of sulphadoxine/pyrimethamine (SP) plus three doses of amodiaquine (AQ))
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Control (SP and AQ placebos)
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: IPTc
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1277
Study: 18647310

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 20
Study: 16478746

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa every 3 weeks (500-microg dose)
Number of subjects: 705

Group type: COMPARATOR
Intervention: Weekly darbepoetin alfa (2.25-microg/kg)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa every 3 weeks
Number of subjects: 705

Group type: COMPARATOR
Intervention: Weekly darbepoetin alfa
Number of subjects: 705
Study: 12777459

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐pertechnetate salivary gland scintigraphy with semiquantitative analysis
Number of subjects: 21
Study: 10843975

Group type: EXPERIMENTAL
Intervention: UMC (University‐affiliated county medical center)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: UMC
Number of subjects: 200

Group type: COMPARATOR
Intervention: HMO
Number of subjects: 200

Group type: COMPARATOR
Intervention: UNMH
Number of subjects: 200
Study: 9327759

Group type: EXPERIMENTAL
Intervention: Saturated diet (16.2% of energy as lauric plus myristic plus palmitic acids)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High trans diet (6.6% of energy as trans‐monoenes)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Oleic diet (16.7% of energy as oleic acid)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Moderate trans diet (3.8% of energy as trans‐monoenes)
Number of subjects: 58
Study: 8260564

Group type: EXPERIMENTAL
Intervention: Intravenous adrenaline infusions
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 44
Study: 3518773

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily + Indomethacin 50 mg twice daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily + Sulindac 200 mg twice daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg once daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31986942

Group type: EXPERIMENTAL
Intervention: Neonatal complications (neonatal sepsis)
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Neonatal complications (IVH/ROP/NEC)
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Low maternal educational score
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Preterm delivery <34 weeks
Number of subjects: 841
Study: 29469206

Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan treatment for 3 months
Number of subjects: 120
Study: 27591767

Group type: EXPERIMENTAL
Intervention: reduced-dose/IR
Number of subjects: 200

Group type: COMPARATOR
Intervention: standard-dose/FBP
Number of subjects: 200
Study: 25211164

Group type: EXPERIMENTAL
Intervention: Music enhanced with positive expectancy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-musical sound enhanced with positive expectancy
Number of subjects: 48

Group type: COMPARATOR
Intervention: No expectancy enhancement (control group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Expectancy-enhanced music (replication cohort)
Number of subjects: 48
Study: 23773313

Group type: EXPERIMENTAL
Intervention: Cleavage-stage embryo biopsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (unbiopsied embryos)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blastocyst biopsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (blastocysts)
Number of subjects: 0
Study: 21226357

Group type: EXPERIMENTAL
Intervention: Equilibrium pressure pneumatic tourniquet (EPPT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Common tourniquet (control group)
Number of subjects: 21
Study: 18538574

Group type: EXPERIMENTAL
Intervention: Static progressive stretch using a patient-directed orthosis for a mean of 9 weeks (range, 3 to 27 weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Static progressive stretch
Number of subjects: 41
Study: 15930221

Group type: EXPERIMENTAL
Intervention: Human milk (HM)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Modified cow's milk formula (MCF) with added cholesterol
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cow's milk formula (CF)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Comparison at 18 months
Number of subjects: 47
Study: 14585532

Group type: EXPERIMENTAL
Intervention: Elastic bands
Number of subjects: 26

Group type: COMPARATOR
Intervention: Weightlifting exercises (Koch press)
Number of subjects: 26
Study: 11064530

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior intervention
Number of subjects: 243

Group type: COMPARATOR
Intervention: Information groups (pamphlet or extensive information package)
Number of subjects: 243

Group type: COMPARATOR
Intervention: All groups (Cognitive-behavior and Information groups)
Number of subjects: 243
Study: 8821311

Group type: EXPERIMENTAL
Intervention: Daily lithium dosing (700 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alternate-day lithium dosing (1200 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 50
Study: 1449443

Group type: EXPERIMENTAL
Intervention: Cholesterol reduction treatment
Number of subjects: 50000
Study: 3937665

Group type: EXPERIMENTAL
Intervention: Levonorgestrel contraceptive implants (NORPLANT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intrauterine device (Cu T380-Ag)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Barrier or no contraception
Number of subjects: 50
Study: 31219771

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nonselective β-adrenergic blockade (40 mg propranolol)
Number of subjects: 16
Study: 29624942

Group type: EXPERIMENTAL
Intervention: HIV testing and counseling (HTC) provided by VHTs
Number of subjects: 256

Group type: COMPARATOR
Intervention: HIV testing and counseling (HTC)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Integrated model of FP and HTC
Number of subjects: 256
Study: 25123239

Group type: EXPERIMENTAL
Intervention: HXLPE liners
Number of subjects: 54

Group type: COMPARATOR
Intervention: UHMWPE liners
Number of subjects: 54
Study: 23547209

Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Belimumab 4 mg/kg
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Belimumab (any dose) in open-label extension
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo switched to belimumab 10 mg/kg in extension
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 21470404

Group type: EXPERIMENTAL
Intervention: K-1 mmol/l
Number of subjects: 24

Group type: COMPARATOR
Intervention: K+1 mmol/l
Number of subjects: 24

Group type: COMPARATOR
Intervention: K
Number of subjects: 24
Study: 19817753

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids + Vitamin D(3)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 16670859

Group type: EXPERIMENTAL
Intervention: Telemedical support (TM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional support and paper diary (PD)
Number of subjects: 36
Study: 14872179

Group type: EXPERIMENTAL
Intervention: One injection of varicella vaccine
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Two injections of varicella vaccine
Number of subjects: 2000
Study: 11434826

Group type: EXPERIMENTAL
Intervention: 90 mg/kg per day for 5 days (n = 398)
Number of subjects: 795

Group type: COMPARATOR
Intervention: 40 mg/kg per day for 10 days (n = 397)
Number of subjects: 795
Study: 9552998

Group type: EXPERIMENTAL
Intervention: Risk appraisal questionnaire
Number of subjects: 5686

Group type: COMPARATOR
Intervention: Health questionnaire alone (Control)
Number of subjects: 5686
Study: 7913801

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 12
Study: 3063288

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 100 mg daily (Group 1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Combination of HCTZ with amiloride (Group 2)
Number of subjects: 32
Study: 30893305

Group type: EXPERIMENTAL
Intervention: Informative, normative and monetary incentives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High baseline users
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-monetary incentives
Number of subjects: 0
Study: 28402745

Group type: EXPERIMENTAL
Intervention: Ularitide (15 ng/kg/min continuous intravenous infusion for 48 hours)
Number of subjects: 2157

Group type: COMPARATOR
Intervention: Placebo (matching placebo for 48 hours)
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Ularitide
Number of subjects: 2157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2157
Study: 25552906

Group type: EXPERIMENTAL
Intervention: Selexipag (400-1,600 μg, administered twice daily for 21 days)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Moxifloxacin (single oral 400 mg dose on day 2 or 24)
Number of subjects: 159
Study: 23868508

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU retinyl palmitate per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (one capsule per day)
Number of subjects: 0
Study: 21606533

Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin therapy for 12 weeks
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin therapy for 24 weeks
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin therapy for 12 or 24 weeks
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Patients carrying CC(rs12979860)
Number of subjects: 341
Study: 19706351

Group type: EXPERIMENTAL
Intervention: Open-ended pain question
Number of subjects: 207

Group type: COMPARATOR
Intervention: Closed-ended pain question
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Follow-up questions
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Multidimensional pain assessment instrument
Number of subjects: 207
Study: 16970162

Group type: EXPERIMENTAL
Intervention: Routine drug and Molida therapy (Group A)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Routine drug only (Group B)
Number of subjects: 136
Study: 15496220

Group type: EXPERIMENTAL
Intervention: Donepezil HCl 5 mg once daily for 15 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sertraline HCl 50 mg once daily for 5 days followed by 100 mg once daily for 10 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Concurrent administration of donepezil HCl and sertraline HCl
Number of subjects: 19

Group type: COMPARATOR
Intervention: Donepezil HCl only
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sertraline HCl only
Number of subjects: 19
Study: 11061497

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 9051387

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8113482

Group type: EXPERIMENTAL
Intervention: Sexual assault prevention program (treatment group)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 360
Study: 2890366

Group type: EXPERIMENTAL
Intervention: Atracurium (primed with 50 micrograms kg‐1)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Atracurium (control, no priming)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Vecuronium (primed with 10 micrograms kg‐1)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vecuronium (control, no priming)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pancuronium (primed with 10 micrograms kg‐1)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Pancuronium (control, no priming)
Number of subjects: 3
Study: 31413088

Group type: EXPERIMENTAL
Intervention: 100 mg iron as ferrous sulfate on alternate days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 200 mg iron as ferrous sulfate on alternate days
Number of subjects: 19

Group type: COMPARATOR
Intervention: 100 mg iron as ferrous sulfate on consecutive days
Number of subjects: 19

Group type: COMPARATOR
Intervention: 200 mg iron as ferrous sulfate on consecutive days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 100 mg iron as ferrous sulfate on alternate days vs 200 mg on consecutive days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Gastrointestinal side effects
Number of subjects: 19
Study: 29669086

Group type: COMPARATOR
Intervention: PA group (physical activity only)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PA + CBT‐P group (physical activity plus cognitive-behavioral therapy for pain)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: WL group (wait-list control)
Number of subjects: 60
Study: 26589765

Group type: EXPERIMENTAL
Intervention: Clinician-Supported PTSD Coach (4 sessions of 20 minutes each)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Self-Managed PTSD Coach (1 session of 10 minutes)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clinician-Supported PTSD Coach
Number of subjects: 20
Study: 25218505

Group type: EXPERIMENTAL
Intervention: Gastrocnemii forces during single-leg jump landing
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Quadriceps forces during single-leg jump landing
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hamstrings forces during single-leg jump landing
Number of subjects: 6
Study: 23322574

Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 19837556

Group type: EXPERIMENTAL
Intervention: Drainage clamping for no less than 4 hours
Number of subjects: 603

Group type: COMPARATOR
Intervention: Immediate release of the drain after elective TKA
Number of subjects: 603
Study: 18639581

Group type: EXPERIMENTAL
Intervention: MSB‐N (Experimental I)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: MSB‐N plus Booster (Experimental II)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Attention placebo control group (C)
Number of subjects: 476